In particular, among deceased-donor LT (DDLT) cohorts, scoring systems such as the Risk Estimation of Tumor Recurrence After Transplant (RETREAT), which integrates additional microvascular invasion status [16], and the recurrence-risk reassessment AFP (R3-AFP) [17], have also been developed and have demonstrated strong predictive performance for HCC recurrence but still require additional factors such as histopathologic differentiation grade. Here, AFP is linked to neoplasm.